en.Wedoany.com Report on Mar 23rd, The complex active pharmaceutical ingredient manufacturer Axplora announced progress on its $60 million investment project for high-potency API manufacturing at its Farmabios site in Gropello Cairoli, Italy. The latest phase includes the construction of a 4,500-square-meter, three-story R&D and laboratory center, designed to accelerate the development process and enable large-scale high-potency API production in an efficient manner.

This investment builds upon recent expansions within the Axplora network, including the expansion of a lyophilization facility in Le Mans, France. Once operational, the new facility will enhance development and analytical capabilities, reduce the complexity of technology transfers, and shorten timelines from early development to commercial production.

Currently, high-potency API molecules account for over 30% of the global drug development pipeline, with more than 1,000 high-potency small molecules in development. The new facility will be equipped with advanced R&D laboratories, quality control laboratories, and microbiology laboratories, directly connected to existing production operations. Concentrating development, analytics, and large-scale high-potency API production within a single specialized site eliminates multi-site delays, improves efficiency, and enhances overall project benefits.

Farmabios already operates one of Europe's larger high-potency API manufacturing suites, built with OEB 5 containment strategies. The site boasts five independent production lines and 105 cubic meters of installed capacity, supporting batch sizes from 0.5 kg to 300 kg. This platform is now fully operational and capable of executing high-volume, high-potency projects immediately.